KR20250035597A - Jak를 억제하기 위한 화합물 및 방법 - Google Patents

Jak를 억제하기 위한 화합물 및 방법 Download PDF

Info

Publication number
KR20250035597A
KR20250035597A KR1020257006096A KR20257006096A KR20250035597A KR 20250035597 A KR20250035597 A KR 20250035597A KR 1020257006096 A KR1020257006096 A KR 1020257006096A KR 20257006096 A KR20257006096 A KR 20257006096A KR 20250035597 A KR20250035597 A KR 20250035597A
Authority
KR
South Korea
Prior art keywords
methyl
methoxy
hydrogen
indol
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257006096A
Other languages
English (en)
Korean (ko)
Inventor
아니카 비르기타 마르가레타 오스트랜드
네일 패트릭 그림스터
사미어 가와트카르
제이슨 그랜트 케틀
매그너스 케이 닐슨
리네트 리스 러스톤
퀴빈 수
멜리사 마리에 바스빈더
존 제임스 윈터-홀트
데동 우
웬잔 양
두도르 그레쿠
제임스 맥캐브
리차드 도날드 와스너
클라우디오 에드문도 추아퀴
Original Assignee
디잘 (지앙수) 파마슈티칼 씨오., 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 filed Critical 디잘 (지앙수) 파마슈티칼 씨오., 리미티드
Publication of KR20250035597A publication Critical patent/KR20250035597A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020257006096A 2015-09-25 2016-09-22 Jak를 억제하기 위한 화합물 및 방법 Pending KR20250035597A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562232629P 2015-09-25 2015-09-25
US62/232,629 2015-09-25
KR1020187008186A KR102774784B1 (ko) 2015-09-25 2016-09-22 Jak를 억제하기 위한 화합물 및 방법
PCT/EP2016/072616 WO2017050938A1 (en) 2015-09-25 2016-09-22 Compounds and methods for inhibiting jak

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187008186A Division KR102774784B1 (ko) 2015-09-25 2016-09-22 Jak를 억제하기 위한 화합물 및 방법

Publications (1)

Publication Number Publication Date
KR20250035597A true KR20250035597A (ko) 2025-03-12

Family

ID=56979589

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257006096A Pending KR20250035597A (ko) 2015-09-25 2016-09-22 Jak를 억제하기 위한 화합물 및 방법
KR1020187008186A Active KR102774784B1 (ko) 2015-09-25 2016-09-22 Jak를 억제하기 위한 화합물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187008186A Active KR102774784B1 (ko) 2015-09-25 2016-09-22 Jak를 억제하기 위한 화합물 및 방법

Country Status (17)

Country Link
US (5) US9714236B2 (https=)
EP (2) EP4219482A1 (https=)
JP (1) JP6767491B2 (https=)
KR (2) KR20250035597A (https=)
CN (4) CN111606893B (https=)
AR (1) AR106138A1 (https=)
AU (1) AU2016328764B2 (https=)
BR (1) BR112018005833B1 (https=)
CA (1) CA2995430C (https=)
DK (1) DK3353168T3 (https=)
ES (1) ES2956642T3 (https=)
MX (1) MX375724B (https=)
PT (1) PT3353168T (https=)
RU (1) RU2760359C2 (https=)
TW (1) TWI740843B (https=)
WO (1) WO2017050938A1 (https=)
ZA (1) ZA201800782B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6767491B2 (ja) * 2015-09-25 2020-10-14 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｊａｋを阻害するための化合物及び方法
MX383920B (es) 2016-05-26 2025-03-14 Recurium Ip Holdings Llc Compuestos inhibidores de egfr.
ES2938648T3 (es) * 2017-01-17 2023-04-13 Astrazeneca Ab Inhibidores selectivos de JAK1
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
EP3823964A1 (en) * 2018-07-18 2021-05-26 Astrazeneca AB A xinafoate salt of a jak inhibiting compound
CA3113732C (en) * 2018-09-21 2023-07-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Aromatic heterocyclic compound with kinase inhibitory activity
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
MX2021012749A (es) * 2019-04-19 2021-11-18 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidor selectivo de la jak1 cinasa.
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
CN111961037B (zh) * 2020-09-17 2021-09-21 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的药物化合物
WO2022111499A1 (zh) * 2020-11-26 2022-06-02 深圳铂立健医药有限公司 一种酰胺化合物、药物组合物及其应用
TW202246243A (zh) * 2021-02-26 2022-12-01 美商泰拉生物科學公司 胺基嘧啶化合物及其使用方法
MX2023010642A (es) 2021-03-11 2023-11-28 Janssen Pharmaceutica Nv Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
WO2025230951A1 (en) * 2024-04-29 2025-11-06 Icahn School Of Medicine At Mount Sinai Method of treating adenoid cystic carcinoma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2364340T3 (es) * 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
JP2009513615A (ja) 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
KR20080110998A (ko) * 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
EA017405B9 (ru) * 2006-12-08 2014-05-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
US9908884B2 (en) * 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
EP2611793A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
JP2014500254A (ja) * 2010-11-09 2014-01-09 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
PE20140146A1 (es) * 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
WO2012116247A1 (en) * 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
CN103797010B (zh) * 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
JP6767491B2 (ja) * 2015-09-25 2020-10-14 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｊａｋを阻害するための化合物及び方法

Also Published As

Publication number Publication date
AR106138A1 (es) 2017-12-13
CA2995430C (en) 2023-07-11
US10654835B2 (en) 2020-05-19
KR20180058719A (ko) 2018-06-01
US10167276B2 (en) 2019-01-01
CN111606893A (zh) 2020-09-01
MX375724B (es) 2025-03-06
JP6767491B2 (ja) 2020-10-14
CN111848586A (zh) 2020-10-30
RU2760359C2 (ru) 2021-11-24
MX2018003590A (es) 2018-11-29
CN111646980A (zh) 2020-09-11
EP3353168A1 (en) 2018-08-01
KR102774784B1 (ko) 2025-02-27
EP3353168B1 (en) 2023-08-30
ZA201800782B (en) 2018-12-19
AU2016328764B2 (en) 2020-07-09
AU2016328764A1 (en) 2018-02-22
JP2018529770A (ja) 2018-10-11
US20170088543A1 (en) 2017-03-30
RU2018112993A (ru) 2019-10-28
US12319670B2 (en) 2025-06-03
EP4219482A1 (en) 2023-08-02
BR112018005833A2 (pt) 2018-10-16
CN111848586B (zh) 2024-05-03
US9714236B2 (en) 2017-07-25
BR112018005833B1 (pt) 2023-10-10
CN108368091A (zh) 2018-08-03
US20170320857A1 (en) 2017-11-09
CN111646980B (zh) 2021-08-27
DK3353168T3 (da) 2023-10-02
CA2995430A1 (en) 2017-03-30
US20220119372A1 (en) 2022-04-21
RU2018112993A3 (https=) 2020-01-30
HK1259422A1 (zh) 2019-11-29
US20210078981A1 (en) 2021-03-18
TWI740843B (zh) 2021-10-01
PT3353168T (pt) 2023-09-20
US20190092760A1 (en) 2019-03-28
ES2956642T3 (es) 2023-12-26
CN111606893B (zh) 2021-05-04
WO2017050938A1 (en) 2017-03-30
TW201730186A (zh) 2017-09-01
US11247983B2 (en) 2022-02-15
CN108368091B (zh) 2020-08-11

Similar Documents

Publication Publication Date Title
KR102774784B1 (ko) Jak를 억제하기 위한 화합물 및 방법
KR20110084993A (ko) 아미노 피라졸 화합물
CN103814032A (zh) 用作端锚聚合酶抑制剂的4-氧代-3,5,7,8-四氢-4H-吡喃并[4,3-d]嘧啶基化合物
WO2017027717A1 (en) Bicyclic fused pyrimidine compounds as tam inhibitors
HK40035295A (en) Compounds and methods for inhibiting jak
HK40026896B (en) Compounds and methods for inhibiting jak
HK40026896A (en) Compounds and methods for inhibiting jak
HK40026768A (en) Compounds and methods for inhibiting jak
HK40026768B (en) Compounds and methods for inhibiting jak
HK40096832A (en) Compounds and methods for inhibiting jak
HK40035295B (zh) 用於抑制jak的化合物和方法
HK1259422B (zh) 用於抑制jak的化合物和方法
HK40085586A (en) Pyridazinyl thiazolecarboxamide compound
HK40084227A (zh) 哒嗪基噻唑甲醯胺类化合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000